Q-omics provides the consensus-scored KLRK1 profile across patient tissues and cancer cell-line models. KLRK1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, KLRK1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, KLRK1 RNA expression shows 16,081 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BLCA, KIRC, and DLBC as cancer lineages where KLRK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLRK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLRK1 survival associations across molecular data types. KLRK1 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLRK1 RNA expression–survival associations across cancer types. High KLRK1 expression shows unfavorable associations in KIRP and KIRC, but favorable associations in BLCA, HNSC, SKCM and CESC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for KLRK1 RNA expression.
This table summarizes KLRK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KLRK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLRK1 shows lower tumor expression in THCA, BRCA and LUSC and higher tumor expression in KIRC, STAD and KIRP. The KIRC box plot shows higher KLRK1 RNA expression in tumor versus normal tissue (log2 FC = +0.452, t-test p < 0.001).
This table shows molecular features associated with KLRK1 in patient tissues and cancer cell lines. In patient samples, KLRK1 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLRK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
